Mary Klix, MD
Hematology & Oncology · Anchorage, AKNPI 1669447595
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,945 of the $12,630 with a category attached, or 86.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations.
Across 465 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Rigel Pharmaceuticals, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$651
- Pfizer$635
- Bristol Myers Squibb$593
- Astellas Pharma US Inc$547
- plus $7K from 54 others
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$1,0008%
- Food & beverage$10,94587%
- Education$5354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 25 | $424,584 |
| ImbruvicaIbrutinib | 21 | $342,143 |
| KisqaliRibociclib Succinate | 11 | $155,773 |
| EliquisApixaban | 19 | $14,324 |
| XareltoRivaroxaban | 13 | $7,823 |
| Letrozole | 54 | $1,948 |
| Anastrozole | 12 | $666 |
| Tamoxifen Citrate | 11 | $344 |
| Hydroxyurea | 11 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $541 | $424,58425 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $413 | $342,14321 claims |
| NovartisKisqali | $519 | $155,77311 claims |
| PfizerEliquis | $635 | $14,32419 claims |
| Johnson & JohnsonXarelto | $502 | $7,82313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other hematology & oncology in Anchorage
- Steven LiuAnchorage$35K
- Max RabinowitzAnchorage$14K
- Mary StewartAnchorage$9K
- Kendal WebbAnchorage$8K
- Natalie WallaceAnchorage$8K
- Shannon SmileyAnchorage$6K
- Charles BuessAnchorage$5K
- Anusiyanthan MariampillaiAnchorage$4K
- Theodore KimAnchorage$2K
- Ellen ChirichellaAnchorage$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.